[Phase II study with methyl-6[[[2-chloroethyl) nitrosoamino] carbonyl] amino]-6-deoxy-alpha-D-glucopyranoside (MCNU) in hematological malignancies].
1983; National Institutes of Health; Volume: 10; Issue: 6 Linguagem: Inglês
Autores
T Masaoka, K Kimura, Taito Miyazaki, Koji Sakurada, H Saitoh, Masanobu Morioka, Noriki Fujimoto, Manabu Musashi, A Wakui, M Yokoyama, Ryohei Kanamaru, M Oguro, T Takagi, C Konda, Tsuyoshi Saitoh, I Nakao, S Harashima, Y. Ohhashi, Y. Sakai, T Sasaki, R Ohno, Yuki Katoh, Kenneth M. Yamada, Yusuke Hirota, Toshio Takada, Akihiro Hoshino, Karen O’Hara, O Kamiya, Tetsuhito Kojima, Kouji Nagata, Tohru Nakamura, Masataka Sasada, Takuro Yonezawa, T Tsubakio, Yoshio Kanayama, T Kitani, Naoyuki Taniguchi, K Yasunaga, Yukinori Okamoto, H Fujitake, A Ohkubo, Atsushi Horiuchi, Kazuo Tsubaki, T Takubo, Hisako Shibata, H Kawagoe, Michinari Hirata, T Matsubuchi, K Nagai, S Fujita,
Tópico(s)Cytokine Signaling Pathways and Interactions
ResumoA total of 117 cases with hematological malignancies were treated with MCNU at doses of 70-100 mg/m2. Following are the results obtained. 1. MCNU showed a marked depression of cells in the cases with CML, polycythemia vera and thrombocythemia. The low level of cells was maintained for 2 to 7 months. 2. A good response was observed in several cases with blastic crises of CML. 3. No response was observed in two cases with acute leukemia. 4. Although a fair response was observed in several cases with malignant lymphoma or multiple myeloma, moderate bone marrow suppression was observed in a majority of the cases.
Referência(s)